Transcatheter Fontan Stenting: Impact on Hepatic Stiffness and Exercise Capacity
Launched by CHILDREN'S HOSPITAL LOS ANGELES · Jul 10, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a procedure called Fontan stenting affects heart function and liver health in young patients who have a single-ventricle heart condition. Specifically, the study looks at children and young adults aged 12 to 21 who have a narrowed part in their heart’s extracardiac Fontan conduit—a tube used to help blood flow in these patients. Researchers want to see if placing a stent (a small mesh tube) to open up this narrowed area improves how well participants can exercise and whether it reduces liver stiffness, which can be a sign of liver problems.
To take part, patients need to have this single-ventricle heart condition and be already scheduled for a heart catheterization procedure, during which the stent may be placed. Participants must weigh at least 50 kg (about 110 pounds) and be able to perform exercise tests. During the study, they will have two exercise tests to measure their heart and lung function and three liver scans to check liver stiffness—both before and after the stent placement. The trial is currently recruiting and welcomes all genders. It’s important to note that some patients won’t be eligible, such as those with certain heart rhythm problems, pacemakers, or who can’t safely perform exercise tests. This study aims to help doctors better understand the benefits of Fontan stenting on overall health and quality of life for patients with this complex heart condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Functionally single-ventricle Fontan-palliated patients undergoing clinically indicated cardiac catheterization
- • Anticipated Fontan stent placement for extracardiac Fontan conduit stenosis at the discretion of the primary operator
- • Weight ≥ 50 kg
- • 12-21 years of age
- Exclusion Criteria:
- • Interrupted IVC
- • Greater than mild atrioventricular valve regurgitation on most recent echocardiogram or MRI (RF \> 20%).
- • Greater than mild systemic ventricular dysfunction on most recent echo or MRI (EF \< 40%).
- • Non-sinus rhythm
- • Pacemaker
- • Inability to perform exercise test due to developmental or physical disability
About Children's Hospital Los Angeles
Children's Hospital Los Angeles (CHLA) is a renowned pediatric healthcare institution dedicated to advancing the health and well-being of children through innovative research and clinical care. As a leading clinical trial sponsor, CHLA is committed to conducting high-quality, ethical research that addresses critical pediatric health issues. With a focus on translating scientific discoveries into effective treatments, CHLA collaborates with multidisciplinary teams and leverages state-of-the-art facilities to support a wide range of clinical trials. Their mission is to enhance the understanding and treatment of childhood diseases, ultimately improving outcomes for young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Neil Patel, MD
Principal Investigator
Children's Hospital Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported